Amitai N, Stafler P, Blau H, et al. - In this investigation involving 64 adolescents [46 in the study group {17 PG (palivizumab group) and 29 NPG (nonpalivizumab group)} and 18 in the control group] aged 15.76 ± 1.52 years, researchers evaluated the long-term impact of palivizumab immunization and extreme prematurity (< 29 weeks gestation) on respiratory symptoms and pulmonary function at adolescence. Study group babies born immediately before palivizumab immunization (NPG) were contrasted with those babies born just after implementation (PG) and a control group. Wheezing episodes, inhaler use, and hospitalizations were uncommon for the study group. According to findings, palivizumab showed no discernable long-term protective effect. Nevertheless, adolescent survivors of extreme prematurity displayed good clinical and physiologic results, except in patients with bronchopulmonary dysplasia for mildly raised lung clearance index. Detected airway hyperreactivity at primary school age, reduced by adolescence.